ArticleCardio-oncology (London, England)2026
Prevalence of obstructive coronary artery disease in asymptomatic cancer patients with elevated troponin levels.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-sensitivity cardiac troponin T (hs-cTnT) is frequently elevated in cancer patients, but its clinical implications remain uncertain. We aimed to determine the prevalence of obstructive coronary artery disease (CAD) as a cause of hs-cTnT elevation and to evaluate the impact of cardiovascular risk factors and oncologic therapies.
methodsBetween 2016 and 2023, 810 consecutive cancer patients with elevated hs-cTnT values presenting to the cardio-oncology outpatient clinic in Heidelberg were included. All patients underwent standardized cardiovascular assessment. Further imaging or invasive evaluation was performed in cases of unexplained biomarker elevation. Logistic regression was applied to identify predictors of CAD. Oncologic therapies were categorized according to ESC cardio-oncology guidelines into low, moderate, or high cardiotoxic risk.
resultsOverall, 340/810 (42.0%) patients revealed alternative explanations for hs-cTnT elevation (e.g., atrial fibrillation, pulmonary embolism, and renal dysfunction). Among the remaining 470/810 (58.0%) patients evaluated for suspected CAD, 47/470 (10.0%) underwent percutaneous coronary intervention for obstructive CAD, whereas 423/470 (90.0%) showed no indication for revascularization. In multivariable analyses, younger age, female sex, preserved left ventricular ejection fraction, and normal NT-proBNP levels were independently associated with the absence of obstructive CAD. Among the 423 patients without obstructive CAD, 286/423 (67.6%) received active oncologic therapy, and 78.3% were exposed to moderate- or high-risk cardiotoxic agents.
conclusionsIn cancer patients with elevated hs-cTnT, obstructive CAD is present in only a minority of cases. Traditional cardiovascular risk factors predict CAD, but therapy- and disease-related cardiac injury appear to be major contributors, highlighting the need for refined risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.